ScholarLens Back to search
2013•The Practical Journal of CancerRequires access

Clinical Value of Serum Thymidine Kinase 1 on the Diagnosis and Clinical Evaluation of Malignant Tumor

Sifeng Liu

Open publisher page 0 citations

Abstract

Objective To explore the clinical value of serum thymidine kinase 1(STK1) on the diagnosis and clinical evaluation of malignant tumor.Methods The levels of STK1 in 100 patients with malignant tumor at different phases of treatment and 20 normal controls were detected by enhanced chemiluminescence assay.Results The level of STK1 of the control group and patient group were(0.62±0.69) pmol/L and(3.65±2.31) pmol/L,respectively(P 0.01).After two cycles of chemotherapy,the level of STK1 in patients with stable disease(SD),progress disease(PD) and partial response(PR) were(3.48±2.82),(5.67±3.57) and(1.63±1.54) pmol/L,respectively.There was a significant statistical difference between the PR group and the PD group(P 0.01).Conclusion STK1 is a useful marker in the diagnosis and evaluation of malignant tumor.

About this research paper

What this paper is about

Objective To explore the clinical value of serum thymidine kinase 1(STK1) on the diagnosis and clinical evaluation of malignant tumor.Methods The levels of STK1 in 100 patients with malignant tumor at different phases of treatment and 20 normal controls were detected by enhanced chemiluminescence assay.Results The level of STK1 of the control group and patient group were(0.62±0.69) pmol/L and(3.65±2.31) pmol/L,respectively(P 0.01).After two cycles of chemotherapy,the level of STK1 in patients with stable disease(SD),progress disease(PD) and partial response(PR) were(3.48±2.82),(5.67±3.57) and(1.63±1.54) pmol/L,respectively.There was a significant statistical difference between the PR group and the PD group(P 0.01).Conclusion STK1 is a useful marker in the diagnosis and evaluation of malignant tumor.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the clinical value of serum thymidine kinase 1(STK1) on the diagnosis and clinical evaluation of malignant tumor.Methods The levels of STK1 in 100 patients with malignant tumor at different phases of treatment and 20 normal controls were detected by enhanced chemiluminescence assay.Results The level of STK1 of the control group and patient group were(0.62±0.69) pmol/L and(3.65±2.31) pmol/L,respectively(P 0.01).After two cycles of chemotherapy,the level of STK1 in patients with stable disease(SD),progress disease(PD) and partial response(PR) were(3.48±2.82),(5.67±3.57) and(1.63±1.54) pmol/L,respectively.There was a significant statistical difference between the PR group and the PD group(P 0.01).Conclusion STK1 is a useful marker in the diagnosis and evaluation of malignant tumor.

Key concepts: Medicine, Internal medicine, Gastroenterology, Malignant disease, Significant difference, Cancer

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Value of Serum Thymidine Kinase 1 on the Diagnosis and Clinical Evaluation of Malignant Tumor — Research Paper | ScholarLens